Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

teva b.v. - paracetamol - suppositorier - 250 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

argenx - efgartigimod alfa - myasthenia gravis - immunosuppressiva - vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

smartpractice denmark aps - alfa-amylcinnamaldehyd, almindelig slåenlav (evernia prunastri), benzocain, benzylparahydroxybenzoat, butylparahydroxybenzoat, chlorquinaldol, cinchocainhydrochlorid, cinnamaldehyd, cinnamylalkohol, clioquinol, cyclohexylbenzothiazylsulfenamid, dibenzothiazyldisulfid, dipentamethylenthiuramdisulfid, diphenylguanidin, disulfiram, epoxyresin, ethylendiamindihydrochlorid, ethylparahydroxybenzoat, eugenol, geraniol, hydroxycitronellal, isoeugenol, kaliumdichromat, koboltchlorid, kolofonium, lanolinalkohol, merc - plaster til provokationstest

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

smartpractice denmark aps - alfa-amylcinnamaldehyd, almindelig slåenlav (evernia prunastri), benzocain, benzylparahydroxybenzoat, butylparahydroxybenzoat, chlorquinaldol, cinchocainhydrochlorid, cinnamaldehyd, cinnamylalkohol, clioquinol, cyclohexylbenzothiazylsulfenamid, dibenzothiazyldisulfid, dipentamethylenthiuramdisulfid, diphenylguanidin, disulfiram, epoxyresin, ethylendiamindihydrochlorid, ethylparahydroxybenzoat, eugenol, geraniol, hydroxycitronellal, isoeugenol, kaliumdichromat, koboltchlorid, kolofonium, lanolinalkohol, mercaptobenzothiazol, methylchlorisothiazolinon, methylparahydroxybenzoat, morpholinylmercaptobenzothiazol, n-cyclohexyl-n-phenylparaphenylendiamin, n-hydroxymethylsuccinimid, n-isopropyl-n-phenylparaphenylendiamin, n,n-diphenylparaphenylendiamin, neomycinsulfat, nikkelsulfat, p-tert butylphenol formaldehyd harpiks, paraphenylendiamin, perubalsam, propylparahydroxybenzoat, quaternium-15, tetracainhydrochlorid, tetramethylthiurammonosulfid, thiomersal, thiram, zinkdibutyldithiocarbamat, zinkdiethyldithiocarbamat - plaster til provokationstest

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

smartpractice denmark aps - alfa-amylcinnamaldehyd, almindelig slåenlav (evernia prunastri), bacitracin, benzocain, benzylparahydroxybenzoat, bronopol, budesonid, butylparahydroxybenzoat, cinnamaldehyd, cinnamylalkohol, clioquinol, cyclohexylbenzothiazylsulfenamid, diazolidinyl urea, dibenzothiazyldisulfid, dipentamethylenthiuramdisulfid, diphenylguanidin, disperse blue 106, disulfiram, epoxyresin, ethylendiamindihydrochlorid, ethylparahydroxybenzoat, eugenol, geraniol, guldnatriumthiosulfat, hydrocortisonbutyrat, hydroxycitronellal, imidurea, isoeugenol, kaliumdichromat, koboltchlorid, kolofonium, lanolinalkohol, mercaptobenzothiazol, methylchlorisothiazolinon, methyldibromoglutharonitrile, methylparahydroxybenzoat, morpholinylmercaptobenzothiazol, n-cyclohexyl-n-phenylparaphenylendiamin, n-hydroxymethylsuccinimid, n-isopropyl-n-phenylparaphenylendiamin, n,n-diphenylparaphenylendiamin, neomycinsulfat, nikkelsulfat, p-tert butylphenol formaldehyd harpiks, paraphenylendiamin, parthenolid, perubalsam, propylparahydroxybenzoat, quaternium-15, tetracainhydrochlorid, tetramethylthiurammonosulfid, thiomersal, thiram, tixocortolpivalat, zinkdibutyldithiocarbamat, zinkdiethyldithiocarbamat - plaster til provokationstest

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

smartpractice denmark aps - alfa-amylcinnamaldehyd, bacitracin, benzocain, benzylparahydroxybenzoat, bronopol, budesonid, butylparahydroxybenzoat, chlorquinaldol, cinchocainhydrochlorid, cinnamaldehyd, cinnamylalkohol, clioquinol, cyclohexylbenzothiazylsulfenamid, diazolidinyl urea, dibenzothiazyldisulfid, dipentamethylenthiuramdisulfid, diphenylguanidin, disulfiram, epoxyresin, ethylendiamindihydrochlorid, ethylparahydroxybenzoat, eugenol, geraniol, guldsodiumthiosulphate, hydrocortisonbutyrat, hydroxycitronellal, imidazolidinyl urea - plaster til provokationstest

Den Europæiske Union - dansk - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinuri, paroxysmal - selektive immunosuppressiva - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - graft afvisning - immunosuppressiva - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

merck europe b.v. - avelumab - neuroendocrine tumorer - andre antineoplastiske midler, monoklonale antistoffer - bavencio er indiceret som monoterapi til behandling af voksne patienter med metastatisk merkel cellecarcinom (mcc). bavencio i kombination med axitinib er angivet for den første linje behandling af voksne patienter med fremskredent renalcellecarcinom (rcc). bavencio is indicated as monotherapy for the first‑line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc) who are progression-free following platinum‑based chemotherapy.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

novo nordisk a/s - eptacog alfa (aktiveret) - hemophilia b; thrombasthenia; factor vii deficiency; hemophilia a - antihemorrhagics - novoseven er indiceret til behandling af blødningsepisoder og forebyggelse af blødning hos dem, der gennemgår kirurgi eller invasive procedurer i følgende patientgrupper:patienter med medfødt hæmofili med inhibitorer for at koagulation faktorer viii eller ix > 5 bethesda enheder (bu), hos patienter med medfødt hæmofili, der forventes at have en høj anamnese svar på faktor viii eller faktor ix administration hos patienter med erhvervet hæmofili;hos patienter med medfødt faktor vii-mangel;hos patienter med glanzmann thrombasthenia ' s med antistoffer til platelet glycoprotein (gp) iib-iiia og / eller human leucocyte antigener (hla), og med tidligere eller nuværende uimodtagelighed over for blodpladetransfusioner. hos patienter med glanzmann thrombasthenia ' s med tidligere eller nuværende uimodtagelighed over for blodpladetransfusioner, eller hvor blodplader er ikke umiddelbart tilgængelige.